Geneva, October 1, 2025. Swiss medtech company Spineart has secured a CHF 25 million investment to accelerate its international growth and bring new technologies to the spine surgery market. The round was supported by long-term partners Gimv and EGS Beteiligungen (EGSB), reaffirming investor confidence in the company’s trajectory.The fresh funding will enable Spineart to scale its presence across Europe and the United States, while further developing its pipeline of implants, navigation tools, and robotics.
Expanding the Frontiers of Spine Surgery
Spineart focuses on creating solutions that improve safety, efficiency, and clinical outcomes in spinal procedures. One of its flagship products, the BAGUERA® C cervical disc, is currently under review by the FDA, highlighting the company’s ambitions in the U.S. market.At the same time, the firm is channeling resources into digital navigation systems and robotic assistance, signaling a clear intent to bring next-generation technology directly into operating rooms.
Strong Growth Track Record
With over 360 employees worldwide, Spineart continues to expand its industrial base. Its new manufacturing site in Reignier, France, has increased production capacity to meet rising global demand.The company projects revenues of €140 million in 2025, marking its fifth year in a row of double-digit growth and averaging a robust 16% CAGR.
Backed by Committed Investors
“This transaction is an important step in our journey toward profitable and sustainable growth,” said Jerome Trividic, CEO of Spineart. “The support of Gimv and EGSB gives us the momentum to expand internationally, advance our innovation pipeline, and deliver better outcomes for patients.”
From Gimv, partners Bart Diels and Gautier Lefebvre emphasized Spineart’s global potential:“Our continued support reflects our strong belief in Spineart’s ability to innovate in spine surgery. It aligns perfectly with our strategy of partnering with healthcare companies that are shaping the future of patient care.”
EGSB also reinforced its long-term view. According to Dominik Sauter and Christian Pfab: “This additional investment demonstrates our commitment to supporting entrepreneurial teams and helping innovative companies succeed on a global stage.”
Outlook
With a growing product portfolio, enhanced manufacturing capabilities, and strong investor backing, Spineart is positioning itself as a key player in advanced spine surgery. The company’s focus on innovation and international expansion places it at the forefront of the next wave of surgical technology.
About Spineart
Spineart is a global fast-growing company in spine surgery innovation, dedicated to accelerating the adoption of cutting-edge technologies for surgeons and hospitals worldwide for the benefit of their patients. Renowned for its commitment to Quality, Innovation, and Simplicity, Spineart continues to push the boundaries of spinal surgery with its comprehensive portfolio of procedural solutions and digital technologies. Spineart was awarded the “Prix de l’Economie Genevoise 2022” for its contribution to technological and scientific innovations, commercial activities, job creations and ESG principles.
Please visit www.spineart.com and follow on LinkedIn. For media inquiries or further information, please contact press@spineart.com